Scipher Medicine is rapidly expanding its precision medicine ecosystem through strategic partnerships aimed at revolutionizing treatment approaches for autoimmune diseases, particularly rheumatoid arthritis (RA).
The company recently announced collaborations with both OMNY Health and Atropos Health, integrating its proprietary PrismRA test data with broader healthcare networks to advance personalized medicine and improve patient outcomes.
Expanding the World's Largest Immunology Clinico-Transcriptomics Dataset
Scipher Medicine, which maintains the industry's largest RA genomic data asset and biobank, is leveraging its PrismRA test to transform rheumatoid arthritis treatment. The blood-based diagnostic test analyzes a patient's molecular signature to identify individuals unlikely to respond to TNF inhibitor (TNFi) therapy, the world's largest selling drug class for RA.
The company has tested over 40,000 rheumatoid arthritis patients using PrismRA, which is the only classifier approved by the Centers for Medicare & Medicaid Services (CMS) in the United States for this purpose.
"We recognized the significant role that clinico-transcriptomic data plays in both treatment decisions and bringing precision medicine to patients," said Dr. Reginald Seeto, President and CEO of Scipher Medicine. "Patients deserve clarity and personalized evidence-based answers when navigating individual treatment options."
OMNY Health Partnership: Integrating Genomic and Clinical Data
The partnership with OMNY Health represents a significant advancement in autoimmune disease research. OMNY Health's electronic health record (EHR) network reaches more than 80 million patients, including nearly 250,000 with rheumatoid arthritis. Their data encompasses critical metrics such as functional status, laboratory values (ESR, CRP), joint counts, CDAI, and DAS28 scores, enabling comprehensive tracking of patient outcomes and disease progression.
By combining Scipher's genomic insights with OMNY's extensive clinical data, researchers and drug developers gain a holistic view of the patient journey. This integration is particularly valuable as biomarker-dependent drugs now constitute 42 percent of FDA approvals.
"At OMNY Health, we are steadfast in our belief that highly targeted therapies and treatments for disease are the key to improving healthcare outcomes," said Dr. Mitesh Rao, Founder and CEO of OMNY Health. "Nearly 50 million Americans suffer from autoimmune diseases, and their patient experiences hold valuable insights that, if extracted, could help drive advancements in precision medicine."
Atropos Health Collaboration: Accelerating Evidence Generation
Simultaneously, Scipher has partnered with Atropos Health to enhance the Atropos Evidence Network and expand the Immunology Multimodal Network on Atropos's GENEVA OS (Generative Evidence Acceleration Operating System).
This collaboration will integrate PrismRA data into Atropos's platform, which already contains over 300 million patient records. Clinicians using Atropos Health's evidence-generating solutions, including Green Button and ChatRWD (healthcare's first AI-powered chat-to-database application), will be able to generate evidence from the immunology multimodal network for shared decision-making in minutes.
"This partnership brings together the power of precision medicine and real-world evidence to improve patient outcomes in rheumatoid arthritis," noted Seeto. "By combining Scipher's unique RA data assets with Atropos Health's cutting-edge AI evidence generation tools, like ChatRWD, we can provide clinicians with powerful tools to make more informed treatment decisions and deliver personalized care."
Impact on Precision Medicine and Patient Care
These partnerships address a critical need in rheumatoid arthritis treatment, where finding the right therapy often involves a trial-and-error approach that can delay effective treatment and potentially worsen outcomes.
PrismRA helps identify patients unlikely to respond to TNFi therapy before treatment begins, allowing physicians to prescribe alternative effective therapies and avoid unnecessary dose escalations or drug cycles. This precision approach gives patients a better chance of achieving treatment targets and improving clinical outcomes.
"Demand for additional data sets from clinicians and researchers continues to grow, and expanding the Atropos Evidence Network with Scipher Medicine will further meet this demand," said Dr. Brigham Hyde, co-founder and CEO of Atropos Health. "Scipher's PrismRA data will ultimately lead to more opportunities to generate rapid evidence with ChatRWD and more rapidly close the evidence gap in medicine."
The Future of Multimodal Data in Autoimmune Disease Research
These collaborations highlight the growing importance of multimodal data integration in advancing precision medicine. By combining genomic, transcriptomic, and clinical data at scale, researchers can identify new biomarkers, develop more targeted therapies, and ultimately improve patient outcomes.
For the approximately 20 million patients globally affected by rheumatoid arthritis, these partnerships represent a significant step toward more personalized and effective treatment approaches. As these data ecosystems continue to grow and evolve, they promise to accelerate the development of precision medicine solutions for autoimmune diseases and beyond.
